EBIT at other companies
Other financials
Where this comes from
Calculated from Travere Therapeutics, Inc.’s reported figures.
The official record: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Travere Therapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Travere Therapeutics, Inc.'s EBIT?
- Travere Therapeutics, Inc. (TVTX) reported EBIT of -$36.92M in Q1 2026.
- How has Travere Therapeutics, Inc.'s EBIT changed year-over-year?
- Travere Therapeutics, Inc.'s EBIT increased by 13.5% year-over-year, from -$42.67M to -$36.92M.
- What is the long-term trend for Travere Therapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s EBIT has grown at a -25.1% compound annual growth rate (CAGR), from -$199.43M to -$62.82M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.